A systemic fungal infection caused by Paracoccidioides brasiliensis that is most often seen in immunocompromised patients. It affects the mucous membranes, lymph nodes, lungs and bones.
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on paracoccidioidomycosis is limited due to its rarity and the fact that it affects fewer than 10,000 people in the U.S. This has resulted in a lack of systematic clinical studies and comprehensive documentation of its clinical features. Additionally, the complexities of the disease and its varied presentations contribute to the challenges in establishing a clear clinical picture.
To navigate paracoccidioidomycosis, consider consulting an infectious disease specialist with experience in fungal infections. They can provide insights into management strategies and potential treatments. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified, staying connected with healthcare professionals can help you find support and information as it becomes available.
Currently, there are several orphan drugs designated for paracoccidioidomycosis, including fosmanogepix, itraconazole, Nikkomycin Z, and olorofim, which are in various stages of development. However, no clinical trials are presently available. For ongoing updates on research, you can search for related studies on ClinicalTrials.gov.
Actionable guidance for navigating care for paracoccidioidomycosis
To navigate paracoccidioidomycosis, consider consulting an infectious disease specialist with experience in fungal infections. They can provide insights into management strategies and potential treatments. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified, staying connected with healthcare professionals can help you find support and information as it becomes available.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on paracoccidioidomycosis is limited due to its rarity and the fact that it affects fewer than 10,000 people in the U.S. This has resulted in a lack of systematic clinical studies and comprehensive documentation of its clinical features. Additionally, the complexities of the disease and its varied presentations contribute to the challenges in establishing a clear clinical picture.
To navigate paracoccidioidomycosis, consider consulting an infectious disease specialist with experience in fungal infections. They can provide insights into management strategies and potential treatments. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified, staying connected with healthcare professionals can help you find support and information as it becomes available.
Currently, there are several orphan drugs designated for paracoccidioidomycosis, including fosmanogepix, itraconazole, Nikkomycin Z, and olorofim, which are in various stages of development. However, no clinical trials are presently available. For ongoing updates on research, you can search for related studies on ClinicalTrials.gov.
Actionable guidance for navigating care for paracoccidioidomycosis
To navigate paracoccidioidomycosis, consider consulting an infectious disease specialist with experience in fungal infections. They can provide insights into management strategies and potential treatments. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified, staying connected with healthcare professionals can help you find support and information as it becomes available.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on paracoccidioidomycosis is limited due to its rarity and the fact that it affects fewer than 10,000 people in the U.S. This has resulted in a lack of systematic clinical studies and comprehensive documentation of its clinical features. Additionally, the complexities of the disease and its varied presentations contribute to the challenges in establishing a clear clinical picture.
To navigate paracoccidioidomycosis, consider consulting an infectious disease specialist with experience in fungal infections. They can provide insights into management strategies and potential treatments. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified, staying connected with healthcare professionals can help you find support and information as it becomes available.
Currently, there are several orphan drugs designated for paracoccidioidomycosis, including fosmanogepix, itraconazole, Nikkomycin Z, and olorofim, which are in various stages of development. However, no clinical trials are presently available. For ongoing updates on research, you can search for related studies on ClinicalTrials.gov.
Actionable guidance for navigating care for paracoccidioidomycosis
To navigate paracoccidioidomycosis, consider consulting an infectious disease specialist with experience in fungal infections. They can provide insights into management strategies and potential treatments. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information. While no patient organizations are currently identified, staying connected with healthcare professionals can help you find support and information as it becomes available.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.